Zobrazeno 1 - 8
of 8
pro vyhledávání: '"D E, Joranson"'
Publikováno v:
European journal of cancer care. 12(1)
Treatment of pain caused by cancer in Italy has been reported to be inadequate for more than a decade. The problem has been documented in the literature by International Narcotics Control Board (INCB) reports that show Italy's low consumption of morp
Autor:
A M, Gilson, D E, Joranson
Publikováno v:
Journal of pain and symptom management. 21(3)
Physicians report that concern about regulatory investigation negatively influences their prescribing of opioid analgesics. The views of medical regulators about the legality of prescribing controlled substances for pain management were studied in 19
Autor:
D E, Joranson, J W, Berger
Publikováno v:
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996). 40(5 Suppl 1)
Undertreatment of pain continues to be a serious public health problem. The use of opioid analgesics is considered essential for chronic pain management and palliative care. Pharmacists are encouraged to become involved in initiatives to improve pain
Autor:
D E, Joranson
Publikováno v:
NIDA research monograph. 131
Publikováno v:
Wisconsin medical journal. 90(12)
This pilot study was designed to evaluate physician knowledge of the controlled substance regulations that govern the prescribing of opioids and whether concerns about regulatory scrutiny affect reported prescribing practices. Two hundred Wisconsin p
Autor:
D E, Joranson
Publikováno v:
Journal of pain and symptom management. 5
Federal and state policy governing opioids is discussed in relation to achieving balance between efforts to control drug abuse and maintain drug availability for legitimate medical purposes. Federal controlled substances law affirms the essential med
Publikováno v:
Journal of Pain and Symptom Management. 2:111-114
Autor:
D A, Treffert, D E, Joranson
Publikováno v:
JAMA. 249(11)
The Controlled Substances Board evaluated the implementation of the National Cancer Institute (NCI) program in Wisconsin that distributes delta 9-tetrahydrocannabinol (delta 9-THC) to cancer chemotherapy patients with nausea and vomiting refractory t